Relay Price To Sales Ratio vs Free Cash Flow Yield Analysis

RLAY Stock

USD 4.70 0.10 2.08%

Relay Therapeutics financial indicator trend analysis is much more than just breaking down Relay Therapeutics prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Relay Therapeutics is a good investment. Please check the relationship between Relay Therapeutics Price To Sales Ratio and its Free Cash Flow Yield accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Relay Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

For more information on how to buy Relay Stock please use our How to Invest in Relay Therapeutics guide.

Price To Sales Ratio vs Free Cash Flow Yield

Price To Sales Ratio vs Free Cash Flow Yield Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Relay Therapeutics Price To Sales Ratio account and Free Cash Flow Yield. At this time, the significance of the direction appears to have strong relationship.

The correlation between Relay Therapeutics' Price To Sales Ratio and Free Cash Flow Yield is 0.64. Overlapping area represents the amount of variation of Price To Sales Ratio that can explain the historical movement of Free Cash Flow Yield in the same time period over historical financial statements of Relay Therapeutics, assuming nothing else is changed. The correlation between historical values of Relay Therapeutics' Price To Sales Ratio and Free Cash Flow Yield is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Price To Sales Ratio of Relay Therapeutics are associated (or correlated) with its Free Cash Flow Yield. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Free Cash Flow Yield has no effect on the direction of Price To Sales Ratio i.e., Relay Therapeutics' Price To Sales Ratio and Free Cash Flow Yield go up and down completely randomly.

Correlation Coefficient

0.64

Relationship Direction	Positive
Relationship Strength	Significant

View All Relationships

Price To Sales Ratio

Price to Sales Ratio is figured by comparing Relay Therapeutics stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Relay Therapeutics sales, a figure that is much harder to manipulate than other Relay Therapeutics multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.

Free Cash Flow Yield

A financial solvency ratio that compares the free cash flow per share a company is expected to earn against its market value per share, calculated as free cash flow per share divided by market price per share.

Most indicators from Relay Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Relay Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Relay Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

For more information on how to buy Relay Stock please use our How to Invest in Relay Therapeutics guide.Selling General Administrative is likely to drop to about 47.6 M in 2024. Issuance Of Capital Stock is likely to drop to about 8.9 M in 2024

	2021	2022	2023	2024 (projected)
Interest Income	830K	8.8M	31.0M	32.6M
Net Interest Income	830K	8.8M	31.0M	32.6M

Interest Income Net Interest Income

Relay Therapeutics fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Capital Surpluse	Capital Lease Obligations	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital
Total Assets		0.85	0.72	0.87	0.99	0.84	0.95	0.83	0.67	-0.44	-0.85	0.9	0.51	0.85	0.75	0.73	0.99	0.95	0.95	-0.95	0.92	0.85	0.83	0.96	-0.93	0.99
Short Long Term Debt Total	0.85		0.64	0.89	0.84	0.66	0.86	1.0	0.85	-0.05	-0.9	0.97	0.13	1.0	0.74	0.73	0.81	0.9	0.91	-0.83	0.89	1.0	0.63	0.85	-0.81	0.84
Other Current Liab	0.72	0.64		0.89	0.63	0.5	0.49	0.65	0.41	-0.69	-0.45	0.69	0.74	0.66	0.57	0.55	0.73	0.58	0.62	-0.5	0.5	0.64	0.85	0.61	-0.46	0.63
Total Current Liabilities	0.87	0.89	0.89		0.8	0.67	0.77	0.91	0.76	-0.39	-0.8	0.92	0.47	0.91	0.78	0.76	0.87	0.81	0.86	-0.73	0.81	0.89	0.75	0.82	-0.7	0.8
Total Stockholder Equity	0.99	0.84	0.63	0.8		0.8	0.96	0.82	0.65	-0.38	-0.84	0.87	0.44	0.83	0.68	0.67	0.97	0.98	0.94	-0.98	0.92	0.84	0.79	0.97	-0.97	1.0
Other Liab	0.84	0.66	0.5	0.67	0.8		0.77	0.65	0.42	-0.44	-0.75	0.78	0.5	0.67	0.9	0.89	0.87	0.81	0.87	-0.73	0.78	0.66	0.67	0.82	-0.72	0.8
Net Tangible Assets	0.95	0.86	0.49	0.77	0.96	0.77		0.84	0.8	-0.16	-0.94	0.88	0.23	0.85	0.71	0.68	0.92	0.95	0.94	-0.98	0.99	0.86	0.62	0.95	-0.98	0.96
Property Plant And Equipment Net	0.83	1.0	0.65	0.91	0.82	0.65	0.84		0.87	-0.05	-0.89	0.97	0.13	1.0	0.75	0.75	0.8	0.88	0.91	-0.81	0.88	1.0	0.61	0.85	-0.78	0.82
Current Deferred Revenue	0.67	0.85	0.41	0.76	0.65	0.42	0.8	0.87		0.22	-0.91	0.8	-0.15	0.86	0.61	0.59	0.63	0.72	0.76	-0.72	0.86	0.85	0.25	0.73	-0.7	0.65
Net Debt	-0.44	-0.05	-0.69	-0.39	-0.38	-0.44	-0.16	-0.05	0.22		-0.01	-0.18	-1.0	-0.07	-0.31	-0.29	-0.5	-0.26	-0.27	0.2	-0.1	-0.05	-0.72	-0.33	0.19	-0.38
Retained Earnings	-0.85	-0.9	-0.45	-0.8	-0.84	-0.75	-0.94	-0.89	-0.91	-0.01		-0.91	-0.07	-0.9	-0.82	-0.79	-0.84	-0.89	-0.93	0.87	-0.98	-0.9	-0.45	-0.89	0.86	-0.84
Accounts Payable	0.9	0.97	0.69	0.92	0.87	0.78	0.88	0.97	0.8	-0.18	-0.91		0.26	0.97	0.82	0.8	0.89	0.9	0.94	-0.84	0.91	0.97	0.71	0.87	-0.82	0.87
Cash	0.51	0.13	0.74	0.47	0.44	0.5	0.23	0.13	-0.15	-1.0	-0.07	0.26		0.15	0.37	0.35	0.56	0.33	0.34	-0.27	0.18	0.13	0.76	0.4	-0.25	0.44
Non Current Assets Total	0.85	1.0	0.66	0.91	0.83	0.67	0.85	1.0	0.86	-0.07	-0.9	0.97	0.15		0.77	0.77	0.82	0.89	0.92	-0.81	0.89	1.0	0.62	0.86	-0.79	0.83
Non Currrent Assets Other	0.75	0.74	0.57	0.78	0.68	0.9	0.71	0.75	0.61	-0.31	-0.82	0.82	0.37	0.77		0.99	0.78	0.75	0.87	-0.6	0.77	0.74	0.51	0.78	-0.58	0.68
Other Assets	0.73	0.73	0.55	0.76	0.67	0.89	0.68	0.75	0.59	-0.29	-0.79	0.8	0.35	0.77	0.99		0.76	0.76	0.87	-0.59	0.74	0.73	0.49	0.78	-0.56	0.67
Cash And Short Term Investments	0.99	0.81	0.73	0.87	0.97	0.87	0.92	0.8	0.63	-0.5	-0.84	0.89	0.56	0.82	0.78	0.76		0.93	0.94	-0.92	0.91	0.81	0.83	0.95	-0.9	0.97
Common Stock Total Equity	0.95	0.9	0.58	0.81	0.98	0.81	0.95	0.88	0.72	-0.26	-0.89	0.9	0.33	0.89	0.75	0.76	0.93		0.98	-0.95	0.94	0.9	0.71	0.98	-0.95	0.98
Common Stock Shares Outstanding	0.95	0.91	0.62	0.86	0.94	0.87	0.94	0.91	0.76	-0.27	-0.93	0.94	0.34	0.92	0.87	0.87	0.94	0.98		-0.9	0.95	0.91	0.68	0.98	-0.89	0.94
Non Current Liabilities Total	-0.95	-0.83	-0.5	-0.73	-0.98	-0.73	-0.98	-0.81	-0.72	0.2	0.87	-0.84	-0.27	-0.81	-0.6	-0.59	-0.92	-0.95	-0.9		-0.95	-0.83	-0.67	-0.94	1.0	-0.98
Capital Surpluse	0.92	0.89	0.5	0.81	0.92	0.78	0.99	0.88	0.86	-0.1	-0.98	0.91	0.18	0.89	0.77	0.74	0.91	0.94	0.95	-0.95		0.89	0.57	0.94	-0.94	0.92
Capital Lease Obligations	0.85	1.0	0.64	0.89	0.84	0.66	0.86	1.0	0.85	-0.05	-0.9	0.97	0.13	1.0	0.74	0.73	0.81	0.9	0.91	-0.83	0.89		0.63	0.85	-0.81	0.84
Other Current Assets	0.83	0.63	0.85	0.75	0.79	0.67	0.62	0.61	0.25	-0.72	-0.45	0.71	0.76	0.62	0.51	0.49	0.83	0.71	0.68	-0.67	0.57	0.63		0.68	-0.66	0.79
Other Stockholder Equity	0.96	0.85	0.61	0.82	0.97	0.82	0.95	0.85	0.73	-0.33	-0.89	0.87	0.4	0.86	0.78	0.78	0.95	0.98	0.98	-0.94	0.94	0.85	0.68		-0.93	0.97
Total Liab	-0.93	-0.81	-0.46	-0.7	-0.97	-0.72	-0.98	-0.78	-0.7	0.19	0.86	-0.82	-0.25	-0.79	-0.58	-0.56	-0.9	-0.95	-0.89	1.0	-0.94	-0.81	-0.66	-0.93		-0.97
Net Invested Capital	0.99	0.84	0.63	0.8	1.0	0.8	0.96	0.82	0.65	-0.38	-0.84	0.87	0.44	0.83	0.68	0.67	0.97	0.98	0.94	-0.98	0.92	0.84	0.79	0.97	-0.97

Click cells to compare fundamentals

Relay Therapeutics Account Relationship Matchups

Relay Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	393.1M	799.8M	1.0B	1.1B	844.0M	838.5M
Short Long Term Debt Total	24.8M	24.4M	22.9M	57.7M	53.5M	33.6M
Other Current Liab	333K	4.2M	12.1M	44.6M	1.2M	1.1M
Total Current Liabilities	12.0M	13.6M	24.3M	63.7M	30.3M	27.6M
Total Stockholder Equity	(180.4M)	763.3M	897.8M	950.2M	752.0M	563.2M
Other Liab	156K	3K	65.3M	32.4M	37.2M	21.6M
Net Tangible Assets	(180.4M)	763.3M	895.5M	947.9M	1.1B	1.1B
Property Plant And Equipment Net	31.7M	28.8M	27.3M	75.4M	68.9M	43.2M
Current Deferred Revenue	3.4M	5.6M	248K	14.9M	17.1M	18.0M
Net Debt	(17.1M)	(423.2M)	(935.2M)	(941.2M)	(90.3M)	(94.8M)
Retained Earnings	(189.5M)	(404.2M)	(768.1M)	(1.1B)	(1.4B)	(1.3B)
Accounts Payable	7.0M	6.4M	8.3M	10.6M	9.2M	8.5M
Cash	42.0M	447.6M	958.1M	998.9M	143.7M	136.5M
Non Current Assets Total	32.5M	29.7M	32.2M	80.3M	73.9M	46.4M
Cash And Short Term Investments	355.8M	678.1M	958.1M	998.9M	750.1M	763.1M
Common Stock Total Equity	4K	90K	109K	121K	139.2K	71.9K
Common Stock Shares Outstanding	4.3M	42.6M	95.1M	112.2M	122.6M	69.5M
Short Term Investments	313.9M	230.4M	678.0M	847.1M	606.4M	490.5M
Liabilities And Stockholders Equity	393.1M	799.8M	1.0B	1.1B	844.0M	838.5M
Non Current Liabilities Total	561.5M	22.9M	86.3M	85.8M	61.7M	58.6M
Capital Surpluse	8.7M	1.2B	1.7B	2.0B	2.3B	2.4B
Capital Lease Obligations	24.8M	24.4M	22.9M	57.7M	53.5M	33.6M
Other Current Assets	4.7M	9.4M	13.2M	15.4M	3.3M	3.1M
Other Stockholder Equity	(529.1M)	1.2B	1.7B	2.0B	2.2B	1.2B
Total Liab	573.5M	36.5M	110.6M	149.6M	92.0M	87.4M
Net Invested Capital	(180.4M)	763.3M	897.8M	950.2M	752.0M	563.2M
Property Plant And Equipment Gross	31.7M	28.8M	41.7M	93.8M	92.5M	53.5M
Total Current Assets	360.5M	770.1M	976.2M	1.0B	770.1M	792.1M
Accumulated Other Comprehensive Income	325K	64K	(1.1M)	(10.4M)	(196K)	(205.8K)
Capital Stock	4K	90K	109K	121K	127K	83.2K
Non Current Liabilities Other	156K	22.9M	86.3M	32.4M	13.2M	12.5M
Net Working Capital	348.6M	756.5M	951.9M	955.8M	739.8M	764.5M
Short Term Debt	1.2M	3.0M	3.7M	8.6M	5.0M	4.0M
Common Stock	4K	90K	109K	121K	127K	83.2K
Property Plant Equipment	31.7M	28.8M	6.5M	11.6M	10.5M	13.2M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
GOOG	Alphabet Inc Class C
GOOG	Alphabet Inc Class C

Additional Tools for Relay Stock Analysis

When running Relay Therapeutics' price analysis, check to measure Relay Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Relay Therapeutics is operating at the current time. Most of Relay Therapeutics' value examination focuses on studying past and present price action to predict the probability of Relay Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Relay Therapeutics' price. Additionally, you may evaluate how the addition of Relay Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Relay Price To Sales Ratio vs Free Cash Flow Yield Analysis

Price To Sales Ratio vs Free Cash Flow Yield

Price To Sales Ratio vs Free Cash Flow Yield Correlation Analysis

Correlation Coefficient

Price To Sales Ratio

Free Cash Flow Yield

Relay Therapeutics fundamental ratios Correlations

Relay Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Relay Therapeutics fundamental ratios Accounts

Also Currently Popular

Additional Tools for Relay Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Property Plant And Equipment Net	+ 1.0	Short Long Term Debt Total
Non Current Assets Total	+ 1.0	Short Long Term Debt Total
Capital Lease Obligations	+ 1.0	Short Long Term Debt Total
Net Invested Capital	+ 1.0	Total Stockholder Equity
Non Current Assets Total	+ 1.0	Property Plant And Equipment Net
Capital Lease Obligations	+ 1.0	Property Plant And Equipment Net

Cash	- 1.0	Net Debt
Net Invested Capital	- 0.98	Non Current Liabilities Total
Capital Surpluse	- 0.98	Retained Earnings
Total Liab	- 0.98	Net Tangible Assets
Non Current Liabilities Total	- 0.98	Net Tangible Assets
Non Current Liabilities Total	- 0.98	Total Stockholder Equity